Nicole E. Kramer

TL;DR: Infliximab did not significantly reduce depressive symptoms compared with placebo in adults with bipolar depression, and a significant treatment-time and childhood maltreatment interaction was observed in which infliximab-treated individuals with childhood history of physical abuse exhibited greater reductions in MADRS total score.

TL;DR: Infliximab significantly improved a measure of anhedonia relative to placebo in adults with bipolar I/II depression at week 6; intervention efficacy was not sustained 6 weeks after the final infusion.

TL;DR: NEVs revealed that infliximab engaged the TNFR/NF-κB neuro-inflammatory pathway in individuals with BD, in a childhood trauma-dependent manner, which was associated with clinical response and brain structural changes.

TL;DR: The findings support the idea that brain insulin signaling is a target for further mechanistic and therapeutic investigations.

TL;DR: The authors identified biologically relevant moderators of response to tumor necrosis factor (TNF)-α inhibitor, infliximab, among 60 individuals with bipolar depression using an iterative, machine learning-based approach.